Editorial
doi: 10.1111/apt.15714.
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world?
Affiliations
- PMID: 32424922
- DOI: 10.1111/apt.15714
Item in Clipboard
Editorial
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world?
Aliment Pharmacol Ther.
2020 Jun.
No abstract available
Comment in
-
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply.Aliment Pharmacol Ther. 2020 Jun;51(11):1200-1201. doi: 10.1111/apt.15724. Aliment Pharmacol Ther. 2020. PMID: 32424927 No abstract available.
Comment on
-
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5. Aliment Pharmacol Ther. 2020. PMID: 32372515
Similar articles
-
Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply.Aliment Pharmacol Ther. 2020 Jun;51(11):1200-1201. doi: 10.1111/apt.15724. Aliment Pharmacol Ther. 2020. PMID: 32424927 No abstract available.
-
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5. Aliment Pharmacol Ther. 2020. PMID: 32372515
-
Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients.Adv Ther. 2024 Nov;41(11):4335-4355. doi: 10.1007/s12325-024-02979-7. Epub 2024 Sep 24. Adv Ther. 2024. PMID: 39316292 Free PMC article.
-
Non-Alcoholic Fatty Liver Disease in HIV Infection.AIDS Rev. 2017 Jan-Mar;19(1):35-46. AIDS Rev. 2017. PMID: 28182612 Review.
-
Non-alcoholic fatty liver disease.Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21. Lancet. 2021. PMID: 33894145 Review.
Cited by
-
Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications.Curr Diab Rep. 2021 Feb 5;21(3):8. doi: 10.1007/s11892-021-01377-5. Curr Diab Rep. 2021. PMID: 33544287 Free PMC article. Review.
-
Editorial: Insights in gastroenterology: 2021.Front Med (Lausanne). 2022 Sep 8;9:1008157. doi: 10.3389/fmed.2022.1008157. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36160135 Free PMC article. No abstract available.
-
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial.Front Med (Lausanne). 2021 Oct 8;8:734847. doi: 10.3389/fmed.2021.734847. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34692725 Free PMC article.
References
REFERENCES
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016;64:73-84.
-
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
-
- Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-654.e9; quiz e39-40.
-
- Loomba R, Wong R, Fraysse J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020. https://doi.org/10.1111/apt.15679
-
- https://www.liverscreen.eu/. Accessed 8/3/2020.